AI Drug Discovery for Pharma and Biotech

Drug discovery

1

drug

With orphan designation

Overview

Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory condition secondary to rheumatic diseases, infections, or malignancies, characterized by excessive cytokine release, multiorgan dysfunction, and hemophagocytosis. Key features include persistent fever, hepatosplenomegaly, hyperferritinemia (often >684 ng/mL), cytopenia, coagulopathy, and elevated liver enzymes [1][6][16]. Mortality ranges from 20-53% without prompt immunosuppression [5][16]. Diagnosis relies on clinical criteria and exclusion of sepsis [6][10].

Population

Primarily affects children with systemic juvenile idiopathic arthritis (sJIA); adults with Still’s disease, SLE, or infections (e.g., CMV, EBV) [1][2][6][16]. Genetic predisposition linked to mutations in cytolytic pathway genes (PRF1, UNC13D) [9][10].

Burden

Mortality rates reach 30% despite treatment [1][5]; delays in diagnosis worsen outcomes [2][16]. Chronic immunosuppression increases infection risks (e.g., Klebsiella, MRSA) [15][20]. Hospital stays average 3+ weeks with frequent ICU admissions [15][19].

Therapies

  • First-line: High-dose methylprednisolone (30 mg/kg pulses) ± IL-1 inhibitors (anakinra) or IFNγ blockers (emapalumab) [3][8][15].

  • Refractory cases: Cyclosporine A (2–7 mg/kg/day), etoposide (HLH-94 protocol), or plasma exchange [3][5][15][18].

  • Emerging options: JAK inhibitors (ruxolitinib) and anti-IL-6 agents (tocilizumab) [8][17].

Categories: rare immunological diseases, rare systemic and rheumatological diseases, rare transplant-related disorders

Research Papers

817 drug discovery papers about Macrophage activation syndrome, with 3 first-in-class and 1 next-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

817 drug discovery papers about Macrophage activation syndrome, with 3 first-in-class and 1 next-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

proteins
2026-09-21 | Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

Macrophage Activation Syndrome (MAS) is a rare, life-threatening hyperinflammatory condition complicating rheumatologic diseases, most commonly Still's disease (SD). Despite increasing awareness and emerging recommendations, MAS treatment remains heterogeneous worldwide. The METAPHOR project aimed to describe real-life therapeutic strategies for MAS, exploring differences across underlying diseases, geographic regions, physician subspecialties, and drug availability. An international web-based survey was developed by a multidisciplinary expert panel together with a patient representative, following a systematic literature review. The survey was anonymously completed through PReS/PRINTO and the Histiocyte Society networks (October-December 2023). Treatment strategies for MAS across different rheumatologic contexts were explored. Responses were analyzed descriptively and stratified by geography, subspecialty, clinical experience, and underlying disease. A total of 287 physicians from 64 countries completed the survey, the majority being pediatric rheumatologists with more than 5 years of experience. Glucocorticoids, particularly intravenous methylprednisolone, were consistently identified as 1st-line therapy across all MAS subtypes (for 44% of clinicians as monotherapy). Anakinra, ciclosporin, and intravenous immunoglobulins were the most frequently combined agents. However, their use varied markedly by underlying disease and geographical region, with anakinra preferentially used in SD-MAS. Striking global disparities in drug availability, particularly for anakinra and emapalumab, significantly influenced treatment choices and were associated with increased reliance on steroid monotherapy. MAS management remains highly heterogeneous worldwide. While glucocorticoids remain foundational, reducing steroid reliance through equitable access to immunomodulatory therapies and advancing mechanism-based strategies represent critical priorities in optimizing MAS care.

Open article ↗



2026-09-16 | Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care.

Hemophagocytic lymphohistiocytosis (HLH) and related cytokine storm syndromes are life-threatening hyperinflammatory disorders that frequently intersect with pediatric critical care. Critically ill children may present with fever, shock, cytopenias, liver dysfunction, coagulopathy, hyperferritinemia, respiratory failure, neurologic deterioration, and multiple organ dysfunction, creating substantial overlap with severe sepsis. Traditional diagnostic criteria remain foundational but do not identify the dominant mechanism or optimal therapy for an individual child. In this review, precision immunomodulation is defined operationally as matching the suspected trigger and clinical phenotype with pathway-informed biomarkers when available, drug-delivery feasibility during organ failure, and the plan for definitive disease control. Interferon-gamma activity may be supported by CXCL9; interleukin (IL)-1/IL-18 biology may support anakinra in macrophage activation syndrome; broader cytokine signaling may support Janus kinase inhibition in selected refractory HLH; and IL-6-directed therapy is primarily syndrome- and grade-directed in immune effector cell cytokine release syndrome. These markers are supportive rather than validated treatment thresholds. Targeted therapy must proceed alongside antimicrobial therapy, source control, organ support, infection surveillance, and early hematopoietic stem cell transplantation planning when indicated. This review provides a bedside framework for phenotype assignment, biomarker interpretation, intensive care unit-focused targeted therapy, extracorporeal bridge strategies, and reassessment at 24-72 h.

Open article ↗



2026-08-01 | An Unusual Case of Infection-Provoked Macrophage Activation Syndrome in Mixed Connective Tissue Disease

Background Compared to systemic lupus erythematosus and adult-onset Still’s disease, mixed connective tissue disease (MCTD) is rarely associated with macrophage activation syndrome (MAS). Viruses, including cytomegalovirus (CMV), may potentiate MAS,[1] often in conjunction with an underlying connective tissue disease.[1-3] Despite this, reports of infection-provoked MAS in adults with MCTD remain very rare.[2,3] Here we describe a case of MAS in a patient with MCTD and concurrent CMV viremia and Clostridioides difficile colitis. Case Report A 65-year-old male was diagnosed with MCTD after presenting with pulmonary arterial hypertension, presumed glomerulonephritis, Raynaud’s phenomenon, and polyarthritis on a background of coronary artery disease and recent NSTEMI requiring stent placement. Investigation revealed a positive ANA (≥1:640, speckled pattern); high-positive anti-RNP-A, Sm/RNP, Ro60/SSA, Ro52/TRIM21, and SSB; and proteinuria. Right heart catheterization and renal biopsy were deferred given dual-antiplatelet therapy and spontaneous renal recovery. He received methylprednisolone prior to a prednisone taper and initiated mycophenolate mofetil (MMF), hydroxychloroquine, macicentan, and tadalafil. He subsequently presented with watery diarrhea, fever (38.5°C), malaise, weight loss and arthralgia. Infectious work-up revealed CMV viremia (serum viral load >4 million/mL) and C. difficile colitis, for which he initiated ganciclovir and oral vancomycin. He was found to have new bicytopenia (hemoglobin 78 g/L, platelet count 175 ×10^9/L), hyperferritinemia (peak 6751 μg/L), hypertriglyceridemia (3.47 mmol/L), hypofibrinogenemia (nadir 1.0 g/L), and elevated aspartate aminotransferase (101 units/L). His C-reactive protein was 21.0 mg/L (peak) and his complement C3 and C4 were normal. Both hematology and rheumatology were consulted, and the patient was diagnosed with MAS. Bone marrow biopsy was deferred given overwhelming evidence for MAS. His MMF was held for diarrhea, and he was initiated on methylprednisolone (250 mg daily for 3 consecutive days, followed by taper) and anakinra (100 mg subcutaneously daily, titrated to 3-times daily) with clinical and biochemical improvement. Conclusion We found only 2 other published English-language adult cases of MAS in conjunction with MCTD in the context of infection. One case was related to histoplasmosis,[2] and the other to an unspecified infection. [3] It is well known that infections can trigger MAS,[1] and while rare, in the appropriate clinical context, MAS should be considered in patients with MCTD who present with an infection and are not improving with standard treatment and whose biochemical parameters suggest MAS. References [1.] Atteritano M. Eur Rev Medi Pharmacol Sci 2012;16:1414-24. [2.] Kawashima H. Intern Med 2025;64:141-6. [3.] Dhote R. Arthritis Rheum 2003;49:633-9.

Open article ↗



2026-06-08 | Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra.

Hyperinflammatory responses substantially contribute to morbidity and mortality in severe COVID-19 and share features with secondary hemophagocytic lymphohistiocytosis and macrophage activation syndrome. The Hyperinflammation in COVID-19 (HIC) criteria allow early diagnosis and may provide a framework for dynamic treatment monitoring. We retrospectively analyzed 218 hospitalized patients with hyperinflammation (HIC ≥35) who received anakinra at a tertiary referral center. The daily anakinra dose (100-800 mg/day, administered intravenously or subcutaneously) was adjusted according to clinical and laboratory parameters. The primary outcome was in-hospital mortality. Secondary outcomes included time to ≥50% CRP reduction, ICU admission, mechanical ventilation, and dynamic changes in ΔHIC and inflammatory biomarkers. Overall mortality was 12.8%. Survivors achieved earlier CRP reduction than non-survivors (3.1 vs. 4.7 days) and showed a progressive decline in HIC, whereas non-survivors had persistently elevated or rising scores. Divergence in ΔHIC and other parameters, including neutrophil count, D-dimer, LDH, procalcitonin, and creatine kinase, emerged within 3-4 days. ROC analysis demonstrated that HIC on the day of anakinra initiation and at the final assessment discriminated survivors from non-survivors (AUC 0.75, p < 0.001; cut-offs 70.8 and 66.5, with high sensitivity but moderate specificity), whereas baseline and first-response-day HIC had limited predictive value (AUC approximately 0.50-0.55) . These findings support the HIC score as both a diagnostic and dynamic monitoring tool during IL-1 blockade. Initiating anakinra when HIC is ≥35 but <70, and reassessing treatment response after 3-4 days using ΔHIC together with CRP kinetics, may help optimize outcomes.

Open article ↗



2026-04-21 | Therapeutic challenges of concurrent pneumonia and disease flare in a patient with Still’s disease and recurrent macrophage activation syndrome

Introduction Still’s disease belongs to non-familial autoinflammatory systemic disorders. Prior distinction of this condition into two separate entities: the systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD), is obsolete, and European Alliance of Associations for Rheumatology recommends that it should be considered as one disease. Case description Patient at age 30, diagnosed with sJIA at 4. The first treatment was high doses of glucocorticosteroids (GCs). At that time, the patient 3 times develop macrophage activation syndrome (MAS). Since 2016, methotrexate (MTX) was prescribed, and in 2022, leflunomide was added as a second drug, but the patients took them irregularly. In 2022, due to a persistent subfebrile state and recurrent arthritis, he was qualified for treatment with tocilizumab at a dose of 400 mg applied in infusions every 4 weeks. Due to a remission state since 2023 multiple attempts to prolong the time between applications were made, but they failed. Finally, in 2025, the duration between dosages was successfully extended to 8 weeks. During therapy, the prior treatment with MTX was recommended but not taken by patients. In January 2026, the patient reported pain in multiple joints, fever, sore throat and rash on his trunk. In addition, patient complains of severe pain in his chest. In laboratory tests, the inflammatory indicators were very high. In the high-resolution computed tomography of the chest, the symptoms of pneumonia were described. Treatment with levofloxacin and a pulse of i.v. methylprednisolone has been introduced with subsequent treatment with prednisolone at a dose 1 mg/kg/day. The regression of changes in the lungs was achieved, the fever did not subside, and inflammatory indicators were still high, pointing to the development of MAS. After administration of tocilizumab, due anakinra was not available, complete remission was achieved. Although the interval from the end of pneumonia treatment was only one week. Due to the reluctance to use MTX, treatment with cyclosporine at a dose of 3 mg/kg/day was proposed. Conclusions The occurrence of severe pneumonia raises concerns about the safety of further tocilizumab treatment. A possible therapeutic option for this patient is interleukin-1 (IL-1) blockade, e.g. anakinra, which, according to the recommendations of the British Society for Rheumatology, is preferred in severe systemic disease over IL-6 blockade. In addition, it has been proven to be safe to use anakinra even in patients with sepsis, so it could be a therapeutic option in this case. Similar data for the use of tocilizumab in bacterial infection is lacking.

Open article ↗



small molecules
2026-09-11 | Unmasking Macrophage Activation Syndrome in Vexas Syndrome: A Diagnostic Challenge.

Vacuoles, E1 Enzyme, X-linked, Auto-inflammatory, Somatic (VEXAS) syndrome is a late-onset autoinflammatory disease caused by somatic mutations in the UBA1gene. Macrophage activation syndrome (MAS) is a rare but life-threatening hyperinflammatory condition whose association with VEXAS syndrome remains poorly described. We report three cases of MAS occurring in men aged 65 to 72 years with genetically confirmed VEXAS syndrome. In all cases, MAS was characterized by fever, recent-onset cytopenias, marked hyperferritinaemia, and a high probability of MAS according to the H-score (>93%). Bone marrow examination demonstrated haemophagocytosis in two patients and numerous activated macrophages in one. Extensive investigations failed to identify infectious, malignant, or drug-related triggers. In one patient, MAS preceded the diagnosis of VEXAS syndrome by several years. In the two others, MAS occurred during the course of established VEXAS disease and was considered a manifestation of disease flare. Treatment included high-dose corticosteroids, with additional anakinra in one patient and etoposide in another, resulting in rapid clinical and biological improvement. One patient experienced MAS relapse following granulocyte colony-stimulating factor exposure during azacitidine treatment, whereas no recurrence was observed in the other two patients during follow-up. MAS appears to be an underrecognized and potentially severe complication of VEXAS syndrome that may occur in the absence of an identifiable infectious or malignant trigger. Diagnostic overlap between both conditions may delay recognition. MAS should be suspected in VEXAS patients presenting with acute cytopenias, marked hyperferritinaemia, and organ involvement. Early use of the H-score, bone marrow examination, and prompt immunosuppressive treatment are essential to improve outcomes. Macrophage activation syndrome (MAS) may represent a severe flare manifestation of Vacuoles, E1 Enzyme, X-linked, Auto-inflammatory, Somatic (VEXAS) syndrome, even in the absence of an identifiable infectious, malignant, or drug-related trigger.The diagnosis of MAS can be challenging in VEXAS syndrome because both conditions share overlapping features, including systemic inflammation, cytopenias, hyperferritinaemia, and bone marrow abnormalities.Recent-onset cytopenias, marked hyperferritinaemia, and organ involvement in patients with VEXAS syndrome should prompt early assessment for MAS using the H-score and bone marrow examination, allowing rapid initiation of immunosuppressive therapy.

Open article ↗



2026-09-02 | Ruxolitinib for rheumatic disease-associated macrophage activation syndrome in children: a retrospective cohort study.

Macrophage activation syndrome (MAS) is a severe, life-threatening complication in pediatric rheumatic diseases. Current treatments are predominantly based on glucocorticoids; however, their long-term use is associated with significant adverse effects. Ruxolitinib, a Janus kinase (JAK) inhibitor, has emerged as a potential treatment option, but clinical evidence in pediatric populations remains limited. This study aimed to evaluate its efficacy and safety in pediatric patients with rheumatic disease-associated MAS (RD-MAS). We retrospectively reviewed the medical records of pediatric patients with RD-MAS treated at Shenzhen Children's Hospital between January 2021 and December 2025. Eligible patients had a confirmed rheumatic disease, fulfilled the 2016 EULAR/ACR classification criteria for MAS, and had complete clinical, laboratory, treatment, and follow-up data. Patients who received ruxolitinib in addition to conventional immunosuppressive therapy were compared with contemporaneous patients treated with conventional immunosuppressive therapy alone. The primary outcome was time to complete remission (CR). Secondary outcomes included remission rates during follow-up, changes in laboratory parameters, glucocorticoid-sparing effect, cumulative glucocorticoid exposure, and adverse events. A total of 21 patients with RD-MAS were included, of whom 10 received ruxolitinib (ruxolitinib group) and 11 received conventional therapy alone (non-ruxolitinib group). In the ruxolitinib group, 10 patients (6 males, 4 females) had underlying diagnoses of systemic juvenile idiopathic arthritis (sJIA, n = 7), systemic lupus erythematosus (SLE, n = 1), or other connective tissue diseases (n = 2). All patients presented with active disease at baseline. 30% (3/10) of patients achieved CR by week 4, and all patients achieved CR by week 48. By week 8, the median prednisone-equivalent dose decreased from 4 mg/kg/day to 0.4 mg/kg/day, and all patients successfully discontinued glucocorticoids by week 48 while maintaining remission. No significant difference in time to CR or infection rates was observed between groups. However, the ruxolitinib group demonstrated significantly lower cumulative glucocorticoid exposure during follow-up. Ruxolitinib-based therapy was associated with sustained disease control and a significant glucocorticoid-sparing effect in pediatric RD-MAS. These findings support that ruxolitinib may serve as a promising steroid-sparing strategy with favorable efficacy and safety for pediatric RD-MAS, although larger prospective studies are warranted.

Open article ↗



2026-08-23 | Myeloid IRF5 is required for TLR7-driven inflammatory hemophagocyte differentiation and Macrophage Activation Syndrome

ABSTRACT In TLR7-driven macrophage activation syndrome (MAS), inflammatory hemophagocytes (iHPCs) differentiate from Ly6C HI monocytes, phagocytose red blood cells and promote disease, including anemia and thrombocytopenia. We demonstrate here that IRF5 is required for iHPC differentiation and MAS in TLR7-overexpressing (TLR7.1) mice. Both constitutive and myeloid-specific Irf5 deletion reduced iHPCs and improved anemia, thrombocytopenia and survival. Furthermore, therapeutic inhibition of IRF5 ameliorated MAS features and reduced splenic and circulating iHPCs. While cell-intrinsic IRF5 expression was required for iHPC differentiation, it was not required for TLR7.1 Ly6C HI monocyte differentiation and monocyte transcriptional programs. We further show that the transcriptome and chromatin landscape changed dramatically as iHPCs differentiated from TLR7.1 Ly6C HI monocytes. Many transcriptional programs gained in iHPCs were enriched in genes associated with IRF5-binding accessible chromatin regions, including those associated with NF-κB signaling, cytokine and chemokine production, and complement activation. Our data suggest that IRF5 collaborates with other transcription factor families, including NF-κB, ETS and AP1 members, to regulate iHPC gene programs. Together, our findings demonstrate that expression of IRF5 in myeloid cells is critical for MAS, for iHPC differentiation, and acts broadly across iHPC-specific gene programs in TLR7-driven inflammation. SUMMARY In TLR7-driven MAS, specialized monocyte-derived inflammatory hemophagocytes promote disease, including anemia and thrombocytopenia. Thulin, Lu et al. show that myeloid cell IRF5 is required for iHPC differentiation from Ly6C HI monocytes and for MAS, and that IRF5 likely partners with other transcription factors, including NF-κB, to shape iHPCs programs.

Open article ↗



2026-08-12 | Ruxolitinib combined with corticosteroids for the successful treatment of kawasaki disease-associated macrophage activation syndrome: a case report.

To explore the diagnostic challenges of Kawasaki disease (KD)-associated macrophage activation syndrome (MAS) and the therapeutic value of ruxolitinib combined with corticosteroids. We retrospectively analyzed the clinical data of one pediatric patient with KD-associated MAS and conducted sorting and analysis of relevant published literature. A 14-month-old male infant presented with fever and rash and was diagnosed with severe KD. Despite initial treatment with intravenous immunoglobulin (IVIG) and aspirin, he developed persistent fever, progressive cytopenia, hepatosplenomegaly, hypofibrinogenemia, hyperferritinemia, reduced NK-cell activity, and extremely elevated soluble interleukin-2 receptor (sCD25), fulfilling the HLH-2004 criteria for MAS. He was successfully treated with ruxolitinib plus methylprednisolone, with rapid resolution of fever, recovery of blood counts, and improvement in coagulation and inflammatory markers. KD-associated MAS is rare but life-threatening. Early recognition of warning signs and prompt initiation of ruxolitinib-based combination therapy can effectively control cytokine storm and improve clinical outcomes.

Open article ↗



2026-08-06 | Unraveling Immune Dysregulation in ZNFX1 Deficiency: From Interferonopathies to Macrophage Activation Syndrome

Abstract Purpose ZNFX1 interferes with early viral replication after exposure to type I interferon, and interacts with mitochondrial antiviral sensors (MAVS) leading to a balanced expression of interferon-stimulated genes (ISGs). ZNFX1 deficiency mimics systemic autoinflammatory diseases and accurate identification may prevent early mortality. We compare a homozygous ZNFX1 frameshift mutation patient to subjects with known interferonopathies. We explore the association between this mutation, unregulated ISGs, and macrophage activation syndrome (MAS). Methods Study participants included our index patient, other patients with well-characterized interferonopathies, and healthy participants. We performed western blotting for ZNFX1 and whole Blood mRNA-seq, RT-qPCR, ELISA, and Olink Proteomics analysis to assess cytokine production and the underlying immune dysregulation. Results Our patient had elevated expression of interferon-inducible genes compared to healthy controls, but levels were comparable to subjects with known interferonopathies. Gene sequencing revealed a novel homozygous ZNFX1 frameshift variant resulting in a truncated protein. Transcriptomic analysis pointed to the top 3 cytokine upstream regulators, tumor necrosis factor (TNF), IL-1β, and interferon-gamma. ZNFX1 deficient patients appear to have a clinical profile that differs from classical type I interferonopathies, including features such as thrombotic microangiopathy (TMA) and a higher frequency of MAS. Conclusions ZNFX1 deficiency is an immune dysregulation disorder characterized by a robust type I interferon signature combined with elevated inflammatory cytokines, leading to severe early-onset multisystem inflammatory disease. Characterizing the immune profile allows targeted short-term treatments that may prolong life.

Open article ↗



cell therapies
2025-09-01 | Allogeneic haematopoietic stem cell transplantation for severe Still's disease: a retrospective report of three paediatric patients.

Severe forms of systemic JIA (sJIA), also called paediatric-onset Still's disease are associated with two major life-threatening complications: macrophage activation syndrome (MAS) and severe lung disease. Patients are usually resistant to conventional synthetic (cs) DMARDs, biologic (b) DMARDs, and targeted synthetic (ts) DMARDs. Recently, allogeneic haematopoietic stem cell transplantation (HSCT) has been performed in a small number of patients with refractory and life-threatening disease. We aimed to report outcomes and complications of allogeneic HSCT in patients with severe, refractory sJIA treated at our centre. We conducted a retrospective, observational, single-centre study in a tertiary paediatric immunology care centre (Necker Hospital, Paris, France). We report three sJIA patients who underwent allogeneic HSCT at a median age of 3.5 years. All had recurrent MAS; two had lung disease and the HLA-DRB1*15 haplotype, associated with severe delayed hypersensitivity to IL-1/IL-6 inhibitors. Donors were matched sibling donors for the first and third patient, and matched unrelated donor for the second patient. They presented multiple post-graft complications: graft-vs-host disease, infections, thrombotic microangiopathy and severe inflammatory complications on previously affected organs, such as skin and lungs. At a median follow-up of 22 months (20-33) after transplantation, they were all in remission with full-donor chimerism and were off immunosuppressive treatment. Allogeneic HSCT can be an effective salvage therapy in patients with refractory sJIA. However, the risk of post-transplant endothelial complications and severe inflammation in previously affected organs, such as joints, skin and lungs deserves particular attention.

Open article ↗



2025-06-01 | POS1430 GENETIC LANDSCAPE OF ADULT-ONSET STILL'S DISEASE WITH MACROPHAGE ACTIVATION SYNDROME: IDENTIFYING KEY RISK LOCI FOR DISEASE MECHANISMS AND PERSONALIZED TREATMENT


Abstract

Background:

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are severe, life-threatening systemic hyperinflammatory syndromes. They can arise from genetic defects as well as various triggers, including infections, malignancies, and autoimmune diseases. MAS is most recognised and best studied in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Currently, research on the underlying pathogenesis of MAS and its treatment options remains insufficient. Recently, the field of genomics has garnered increasing attention.

Objectives:

The objective of this study is to identify the genetic variants associated with AOSD-MAS susceptibility and to elucidate their connections to specific target genes. Such insights are critical for advancing the clinical translation of genetic discoveries, thereby enhancing the accuracy of diagnostic genetic screenings and informing personalized therapeutic strategies.

Methods:

In this study, we performed whole-exome sequencing (WES) on a cohort of AOSD patients to identify potential genetic variations, followed by Sanger sequencing for validation. RNA sequencing (RNA-seq) was conducted to explore gene expression profiles. Statistical analyses were carried out using Fisher's exact test (two-sided) to assess associations, and survival analysis was employed to evaluate outcomes.

Results:

This study investigated the genetic predisposition of AOSD-MAS, highlighting the critical involvement of known causative genes for primary HLH (pHLH-KG) and the candidate genes in AOSD-MAS. Among the 72 AOSD-MAS patients, 19 individuals (19/72, 26.39%) harbored mutations in pHLH-KG genes, including LYST, PRF1, STX11, UNC13D, NLRC4, STXBP2, AP3B1, CTPS1, RASGRP1, NCKAP1L, and RC3H1. Gene level comparisons demonstrated that ADGRE2, TGFB1, C6, IKZF3, MPO, POLD1, LIFR, IL15RA, and FANCC were significantly enriched in AOSD-MAS compared to AOSD without MAS (AOSD-nMAS), with notable differences (log2OR > 1 or infinite, p-value < 0.05). At the variant level, significant differences were observed for LYST p.I2666N, STX11 p.A125V, POLA1 p.V539M, LRBA p.E88A, ERCC4 p.G912R, and ADGRE2 p.C29Y (p-value < 0.05). These findings strongly suggest that ADGRE2 plays a pivotal role in the pathogenesis of AOSD-MAS. Additionally, we also conducted gene-phenotype correlation analysis, which revealed that CSF2RB and MECOM were significantly more prominent in refractory AOSD-MAS. In conclusion, the potential synergistic interactions among these genes may contribute critically to the development of AOSD-MAS.

Conclusion:

Our study identified mutations in known HLH-associated genes as well as new candidate genes in AOSD-MAS through WES. Gene-phenotype correlation analysis revealed differences in gene profiles across different clinical phenotypes, providing insights for the precision therapies for AOSD-MAS.

REFERENCES:

NIL.

Acknowledgements:

NIL.

Disclosure of Interests:

None declared. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.


Open article ↗



2025-03-07 | Influence of CAR T-cell therapy associated complications.

Since the introduction of chimeric antigen receptor (CAR) T-cell therapy, it has elicited an immense response in both targeted and residual cancers. Its clinical efficacy is often accompanied by a group of side effects that may become serious because of factors such as tumor burden, the extent of lymphodepletion, and the type of co-stimulus. It is also crucial to know the common toxicities associated with CAR T-cell therapy, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cardiotoxicity, metabolic disorders, pulmonary toxicity, macrophage activation syndrome (MAS), prolonged cytopenia, coagulation disorders, and potential off-target effects on various organs. If not well managed, these can be fatal. However, knowledge about molecular pathways, calcineurin inhibitors, IL-6 receptor antagonists, steroids, suppression of nitric oxide synthase, various therapeutic approaches, and other recent advances have been developed to mitigate the fatal results of various short-term and chronic adverse events related to CAR T-cell therapy. This study provides a comprehensive perspective on contemporary management strategies and presumed causative processes of CAR T-cell-related adverse effects, albeit with several limitations. When CAR T-cell complications, costs, and challenges of toxicity management are properly considered, the CAR T-cell therapy of the future will include a number of toxicity-escaping options.

Open article ↗



2024-08-08 | Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis.

Hemophagocytic lymphohistiocytosis (HLH) can be considered as a severe cytokine storm syndrome disorder. HLH typically manifests as a life-threatening inflammatory syndrome characterized by fevers, cytopenias, hepatosplenomegaly, and various other accompanying manifestations such as coagulopathy, hepatitis or liver failure, seizures or altered mental status, and even multi-organ failure. Standard up-front treatments do not always bring HLH into remission or maintain adequate response, and salvage or alternative therapies are often needed. For patients with genetic diseases that cause HLH, curative allogeneic hematopoietic cell transplantation is usually offered to prevent future episodes of life-threatening HLH. Here, we will discuss the options and approaches for salvage therapy and hematopoietic cell transplantation for patients with HLH.

Open article ↗



2024-06-22 | Optimization Strategies in CAR T-cell Therapy: A Comprehensive Evaluation of Cytopenia, HLH/MAS, and Other Adverse Events.

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for various hematological malignancies. Still, its remarkable efficacy is accompanied by unique adverse events that must be carefully managed. This comprehensive literature review evaluates the safety profile of CAR T-cell therapy, focusing on cytopenia, hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS), and other potential complications. Cytopenia, characterized by reduced blood cell counts, affects a significant proportion of patients, with rates of anemia, neutropenia, and thrombocytopenia reaching up to 60%, 70%, and 80%, respectively. Risk factors include high tumor burden, prior chemotherapy, and bone marrow involvement. Cytokine release syndrome (CRS) occurs in 13% to 77% of patients and is linked to the cytokine storm induced by CAR T cells, target antigen expression, and preexisting immune dysregulation. Other notable adverse events discussed are cytokine release syndrome, neurotoxicity, and infections. Understanding the mechanisms, risk factors, and management strategies for these adverse events is crucial for optimizing patient outcomes and unlocking the full potential of this revolutionary therapy. The review highlights the need for continued research, interdisciplinary collaboration, and evidence-based approaches to enhance the safety and efficacy of CAR T-cell therapy.

Open article ↗



antibodies
2026-09-11 | Macrophage activation syndrome in systemic lupus erythematous and Still's disease: distinct phenotypes shaped by the underlying diseases.

Macrophage activation syndrome (MAS) is a severe complication of Still's disease (SD-MAS), but may also, albeit rarely, complicate SLE (SLE-MAS). The clinical profile of SLE-MAS compared with SD-MAS remains unclear, as do the optimal treatment strategies. A retrospective multicentre cohort of adults with a history of SLE-MAS or SD-MAS was gathered from eight tertiary referral centres. MAS clinical/laboratory features, treatments and outcomes were compared; 'inaugural MAS' was defined if occurring within 6 months from the onset of the underlying disease. Exploratory multivariable profiling assessed for disease-specific features. The SLE-MAS group was also compared with large historical SLE cohorts to identify candidate risk signals. While SD-MAS aligned with the prototypical hyperinflammatory pattern (more marked hyperferritinemia, very high CRP, organomegaly and liver injury; 100% meeting 2016 ACR/EULAR/PRINTO criteria), SLE-MAS (92% meeting criteria) more often featured CNS dysfunction, less liver injury, greater degree of cytopenias including anaemia, with a strong signal of autoimmune haemolysis (73% direct Coombs [DCT] positivity). Therapeutically, IL-1 antagonism was used in seven SLE-MAS with mixed results without any rapid MAS resolution. Mucocutaneous disease, autoimmune haemolysis, CNS involvement, less pronounced female preponderance and much higher DCT positivity dominated the SLE-MAS phenotype compared with historical SLE cohorts comprising 1000, 2228 and 2055 cases each. SLE-MAS diverged from SD-MAS with less organomegaly and liver injury but more pronounced CNS involvement and hematological involvement, the latter strongly linked to red blood cell directed autoantibodies. These findings indicate that SLE-MAS pathogenesis may be divergent and require distinct therapeutic approaches beyond extrapolation from SD-MAS.

Open article ↗



2026-09-10 | Spatial transcriptomics reveals distinct phenotype of proliferating and interferon-activated T lymphocytes in macrophage activation syndrome driven liver inflammation in systemic juvenile idiopathic arthritis

Identify pathways and candidate biomarkers that distinguish various liver pathologies in systemic juvenile idiopathic arthritis (SJIA) with the focus on liver-predominant macrophage activation syndrome (SJIA-MAS). Formalin-fixed, paraffin-embedded liver tissues from SJIA-MAS ( n = 6), SJIA without MAS ( n = 1), autoimmune hepatitis (AIH, n = 7), familial HLH (FHLH, n = 6), steatohepatitis (SH, n = 3), and controls (Ctrl, n = 3) were analyzed by histology and using the NanoString GeoMx Digital Spatial Profiler (DSP). CD3E, CD68 and cytokeratin 8/18 antibodies were used to select regions enriched for T lymphocytes, macrophages, or hepatocytes, respectively. Spatially resolved gene expression data was Q3-normalized and subjected to principal component and clustering analysis. Differentially expressed genes were identified using Mann-Whitney U-test. Histologically, SJIA-MAS liver biopsies were distinguished by extensive portal and intra-sinusoidal expansion of activated CD163 + histiocytes and T lymphocytes (predominantly CD8+). Spatial transcriptomics revealed a markedly distinct phenotype in T lymphocyte enriched regions in SJIA-MAS liver tissue. In addition to pathways driving activation and survival, T lymphocyte regions in SJIA-MAS were distinguished by activation of IFNƔ-induced signaling including CXCL9 overexpression. Strong IFN-induced signatures were also observed in hepatocyte-enriched areas in SJIA-MAS and FHLH. T cell regions in SJIA-MAS could be distinguished by upregulated IFN-induced signaling. Considering that T cells have emerged as the main source of IFN-Ɣ in MAS, this may reflect an amplification loop contributing to uncontrolled activation and expansion of these cells. Our data also suggest that in SJIA-MAS, IFN-Ɣ may be a direct driver of liver injury and, therefore, serve as a therapeutic target.

Open article ↗



2026-09-07 | AMETHYST: a Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-refractory Macrophage Activation Syndrome Complicating Still's Disease.

Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life-threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult-onset Still's disease [AOSD]). AMETHYST aimed to describe real-world treatment patterns and outcomes in glucocorticoid (GC)-refractory MAS complicating Still's disease. In this retrospective cohort study, medical data from January 1, 2012, to March 31, 2023, were abstracted from charts of all eligible patients across eight sites in Europe, Canada, and the US for index MAS episodes (occurring between January 1, 2012, and September 30, 2022, and meeting eligibility criteria). Overall, 55/64 (86%) included patients had sJIA and 9/64 (14%) had AOSD. Most patients (53/64 [82.8%]) were children at index (median age: 7.0 years). MAS was characterized by rash (60.4%), fever (52.8%), and hepatic involvement (49.1%). All patients received GCs; most were also treated with anakinra (48/64 [75%]) and/or ciclosporin (33/64 [51.6%]). Normalization of 7 (complete MAS laboratory remission) or ≥3 (partial remission) prespecified laboratory parameters occurred in 7/64 (10.9%) and 41/64 (64.1%) patients, respectively. GCs were tapered in 50/64 (78.1%) patients (median: 39.9 days). Per investigator assessment of clinical signs/symptoms for the index MAS episode, 24/64 (37.5%) and 26/64 (40.6%) patients had a complete and partial response, respectively. MAS recurred in 20/64 (31.3%) patients. There were 7/64 (10.9%) deaths; estimated 1-year survival probability was 93.75%. Low MAS laboratory remission rates and toxicities of high-dose GCs combined with other treatments highlight the need for safer, more effective therapies.

Open article ↗



2026-09-05 | Macrophage activation syndrome as a rare complication of atypical Kawasaki Disease

No abstract abstract

Open article ↗



2026-09-02 | Analysis code for: VEXAS and Macrophage Activation Syndrome — clinical and multiomic approach of a unique hyperinflammatory clinical dyad

Analysis code and de-identified source data reproducing the cytokine, flow-cytometry, Olink Reveal proteomic and whole-exome summary results reported in the manuscript. Raw sequence data and the full proteomic plate export are not included; they are deposited under controlled access (see the manuscript's Data Availability statement).

Open article ↗



other
2026-09-26 | The Silent Vehicle: Validating the Biological Signals and Noises of Baculovirus Vectors in Macrophage-Targeted Vaccines.

The Baculovirus Expression Vector System (BEVS) is an established eukaryotic platform for high-yield recombinant protein production and is widely utilized for generating vaccine antigens, including recombinant classical swine fever virus E2 glycoprotein, African swine fever virus structural proteins (p72, p30, and p54), and porcine reproductive and respiratory syndrome virus envelope proteins GP5 and M. These antigens interact with macrophage-associated receptors, including CD163 and CD206, to modulate immune responses through macrophage polarization. However, whether baculovirus vector-derived components intrinsically influence macrophage polarization remains unclear, raising concerns regarding potential impacts on biological activity, vaccine efficacy, and downstream purification strategies. In this study, an M2-like tumor-associated macrophage (TAM) model capable of repolarizing toward an M1-like phenotype was established to distinguish the transcriptomic effects of the baculovirus vector control (VC) from those of the recombinant antigen (A1). Comparative RNA sequencing, Gene Set Enrichment Analysis (GSEA), functional enrichment analyses, and linear regression analysis were performed to evaluate vector- and antigen-associated transcriptional responses. Comprehensive transcriptomic analysis showed that VC treatment induced only minimal transcriptomic alterations, with limited immune-related pathway enrichment and expression profiles that remained highly similar to those of untreated M2-like TAMs. Furthermore, linear regression analysis demonstrated negligible correlations between VC-induced and A1-induced transcriptional responses indicating that the limited changes associated with the vector backbone did not correspond to the receptor-mediated immune responses elicited by the recombinant antigen. In contrast, A1 stimulation induced distinct transcriptional reprogramming characterized by enrichment of pro-inflammatory and immune-activation pathways and a shift toward an M1-like macrophage phenotype. These findings suggest the negligible correspondence between VC- and A1-induced transcriptional profiles further supports the transcriptomic noises and signals of the baculovirus vector and inserted proteins, reinforcing its suitability as a platform for macrophage-targeted vaccine development while providing a basis for future optimization of downstream purification strategies.

Open article ↗



2026-03-08 | Is a variant of uncertain significance always 'insignificant'? A systematic review on PRF1 A91V in Hemophagocytic Lymphohistocytosis and comparative analysis with Still's disease.

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder that may arise secondary to rheumatic diseases such as Still’s disease, where macrophage activation syndrome (MAS) represents its clinical counterpart. The pathogenic significance of the PRF1 A91V variant remains uncertain, although functional data suggest partial perforin dysfunction and a possible contribution to late-onset or atypical HLH. This study aimed to clarify the clinical implications of the PRF1 A91V variant through a systematic review of published HLH and MAS cases and a comparative analysis with a single-center Still’s disease cohort. A total of 20 studies, including 38 individual HLH or MAS cases carrying the PRF1 A91V variant, were identified. The median age at diagnosis was 22 years, and 18.4% of patients were homozygous. Fever (82.6%), splenomegaly (57.9%), and hepatomegaly (36.8%) were the most frequent clinical findings. Anemia (57.1%) and thrombocytopenia (85.7%) were the predominant laboratory abnormalities, accompanied by marked hyperferritinemia (median 9319 ng/mL). Compared with 43 active Still’s disease cases, PRF1-mutated HLH patients showed significantly higher rates of cytopenias, hepatomegaly, and central nervous system involvement, together with substantially elevated ferritin levels (9,193 vs 800 ng/mL, p = 0.0023), whereas C-reactive protein levels were comparable. Receiver-operating characteristic analysis identified a ferritin cutoff of 7000 ng/mL (sensitivity 63.2%, specificity 84.6%) as the optimal discriminator for PRF1 A91V positivity. In multivariate regression, ferritin ≥ 7,000 ng/mL remained the only independent predictor (OR 17.3, 95% CI 2.0–146.3, p = 0.009). Patients carrying the PRF1 A91V variant represent a distinct subgroup within the spectrum of hyperinflammatory syndromes. Extreme hyperferritinemia combined with cytopenias should raise suspicion for perforin-related HLH rather than cytokine-driven MAS or classic Still’s disease. Recognition of this variant as a risk-modifying allele may guide early genetic testing and therapeutic decisions, including consideration of advanced interventions in selected cases. The online version contains supplementary material available at 10.1186/s13023-026-04296-4.

Open article ↗



2025-06-27 | Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study.

Background: The introduction of biological drugs into clinical practice for the treatment of children with systemic juvenile idiopathic arthritis (sJIA) allows disease control but increases the risk of infectious events. Infectious events cause immunosuppressive therapy interruptions, leading to disease flare and life-threatening complications, namely macrophage activation syndrome. Our study aimed to evaluate the efficacy and safety of simultaneous vaccination against pneumococcal and Haemophilus influenzae type b (Hib) in children with sJIA. Methods: This study included 100 sJIA patients receiving immunosuppressive therapy who were simultaneously vaccinated against pneumococcal and Haemophilus influenzae type b (Hib) infections. The mean age of disease onset was 5.5 years. The median age at vaccination was 10 ± 4.5 years. Clinical and laboratory parameters of sJIA activity, immunization efficacy, and safety, including anti-SP and anti-Hib IgG antibodies, as well as all vaccination-related adverse events (AEs), were recorded in every patient before, 3 weeks after, and 6 months after vaccination. Results: At the time of vaccination, 29% of patients did not meet the criteria for the inactive disease stage, as defined by C. Wallace: active joints were present in 34.5% of patients, systemic manifestations (rash and/or fever) were present in 41.3%, and 24.2% of patients had solely inflammatory laboratory activity. The protective titer of anti-SP and anti-Hib IgG antibodies was detected in the majority of patients 3 weeks after vaccination (100% and 93%, respectively). The results remained unchanged (99% and 92%, respectively) for 6 months of follow-up, compared to the baseline (91% and 37%, p = 0.000001). Anti-SP IgG and anti-Hib titers raised from 48.3 (18.2; 76.5) and 0.64 (0.3; 3.2) U/mL at the baseline to 103.5 (47.3; 185.4) and 4 (3.5; 4.2) U/mL at D22 and 105 (48.7; 171.8) and 4 (3.8; 4) U/mL (EOS), respectively. Immunosuppressive therapy regimens (combined therapy or biological disease-modifying antirheumatic drug monotherapy) did not influence the immunogenic efficacy of vaccination. The incidence of infectious complications (p = 0.0000001) and antibiotic prescriptions (p = 0.0000001) decreased by more than two times, to 29.9 and 13.8 events per 100 patient months, respectively, within 6 months after vaccination-the average duration of acute infectious events was reduced by five times after immunization (p = 0.0000001). Vaccination did not lead to disease flare: the number of patients with active joints decreased by half compared to the baseline, and the number of patients with systemic manifestations decreased by six times. All vaccine-associated adverse events were considered mild and resolved within 1-2 days. Conclusions: Simultaneous vaccination against pneumococcal and Hib infections in sJIA children is an effective and safe tool that reduces the number and duration of infectious events and does not cause disease flare-ups.

Open article ↗



2025-04-16 | Macrophage Activation Syndrome in Adult-Onset Still's Disease: Challenges in Early Detection and Management.

Adult-onset Still's disease (AOSD) is an immunological disorder that manifests with fever, evanescent rash, leukocytosis, and arthralgia. One of the most severe complications of AOSD is macrophage activation syndrome, a life-threatening complication characterized by hyperactivation of the immune system and multiorgan dysfunction. This case report describes a 24-year-old female who developed macrophage activation syndrome in the setting of AOSD. Initially, she developed heterogeneous and nonspecific symptoms of fever, pharyngitis, rash, lymphadenopathy, and migratory arthralgia after a trip to Mexico. Thus, the diagnosis and appropriate treatment were delayed. Although her symptoms were temporarily relieved with oral steroids, she worsened clinically. She developed a widespread rash, persistent fever, a very high ferritin level (29,972 ng/mL), and elevated liver enzymes with mild hepatosplenomegaly, raising concern for macrophage activation syndrome. After ruling out infections, she was diagnosed with AOSD, and treatment with intravenous steroids was started, resulting in clinical improvement. Macrophage activation syndrome is a rare but fatal complication. Early recognition, particularly with elevated ferritin, liver dysfunction, and thrombocytopenia, is very important. Early intervention with glucocorticoids and biologics like anakinra is crucial for improving outcomes. The patient is in remission with ongoing follow-up with rheumatology.

Open article ↗



2024-10-29 | Functional role of UNC13D in immune diseases and its therapeutic applications.

UNC13 family (also known as Munc13) proteins are evolutionarily conserved proteins involved in the rapid and regulated secretion of vesicles, including synaptic vesicles and cytotoxic granules. Fast and regulated secretion at the neuronal and immunological synapses requires multiple steps, from the biogenesis of vesicles to membrane fusion, and a complex array of proteins for each step. Defects at these steps can lead to various genetic disorders. Recent studies have shown multiple roles of UNC13D in the secretion of cytotoxic granules by immune cells. Here, the molecular structure and detailed roles of UNC13D in the biogenesis, tethering, and priming of cytotoxic vesicles and in endoplasmic reticulum are summarized. Moreover, its association with immune diseases, including familial hemophagocytic lymphohistiocytosis type 3, macrophage activation syndrome, juvenile idiopathic arthritis, and autoimmune lymphoproliferative syndrome, is reviewed. Finally, the therapeutic application of CRISPR/Cas9-based gene therapy for genetic diseases is introduced.

Open article ↗



proteins
2026-09-21 | Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

Macrophage Activation Syndrome (MAS) is a rare, life-threatening hyperinflammatory condition complicating rheumatologic diseases, most commonly Still's disease (SD). Despite increasing awareness and emerging recommendations, MAS treatment remains heterogeneous worldwide. The METAPHOR project aimed to describe real-life therapeutic strategies for MAS, exploring differences across underlying diseases, geographic regions, physician subspecialties, and drug availability. An international web-based survey was developed by a multidisciplinary expert panel together with a patient representative, following a systematic literature review. The survey was anonymously completed through PReS/PRINTO and the Histiocyte Society networks (October-December 2023). Treatment strategies for MAS across different rheumatologic contexts were explored. Responses were analyzed descriptively and stratified by geography, subspecialty, clinical experience, and underlying disease. A total of 287 physicians from 64 countries completed the survey, the majority being pediatric rheumatologists with more than 5 years of experience. Glucocorticoids, particularly intravenous methylprednisolone, were consistently identified as 1st-line therapy across all MAS subtypes (for 44% of clinicians as monotherapy). Anakinra, ciclosporin, and intravenous immunoglobulins were the most frequently combined agents. However, their use varied markedly by underlying disease and geographical region, with anakinra preferentially used in SD-MAS. Striking global disparities in drug availability, particularly for anakinra and emapalumab, significantly influenced treatment choices and were associated with increased reliance on steroid monotherapy. MAS management remains highly heterogeneous worldwide. While glucocorticoids remain foundational, reducing steroid reliance through equitable access to immunomodulatory therapies and advancing mechanism-based strategies represent critical priorities in optimizing MAS care.

Open article ↗



2026-09-16 | Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care.

Hemophagocytic lymphohistiocytosis (HLH) and related cytokine storm syndromes are life-threatening hyperinflammatory disorders that frequently intersect with pediatric critical care. Critically ill children may present with fever, shock, cytopenias, liver dysfunction, coagulopathy, hyperferritinemia, respiratory failure, neurologic deterioration, and multiple organ dysfunction, creating substantial overlap with severe sepsis. Traditional diagnostic criteria remain foundational but do not identify the dominant mechanism or optimal therapy for an individual child. In this review, precision immunomodulation is defined operationally as matching the suspected trigger and clinical phenotype with pathway-informed biomarkers when available, drug-delivery feasibility during organ failure, and the plan for definitive disease control. Interferon-gamma activity may be supported by CXCL9; interleukin (IL)-1/IL-18 biology may support anakinra in macrophage activation syndrome; broader cytokine signaling may support Janus kinase inhibition in selected refractory HLH; and IL-6-directed therapy is primarily syndrome- and grade-directed in immune effector cell cytokine release syndrome. These markers are supportive rather than validated treatment thresholds. Targeted therapy must proceed alongside antimicrobial therapy, source control, organ support, infection surveillance, and early hematopoietic stem cell transplantation planning when indicated. This review provides a bedside framework for phenotype assignment, biomarker interpretation, intensive care unit-focused targeted therapy, extracorporeal bridge strategies, and reassessment at 24-72 h.

Open article ↗



2026-08-01 | An Unusual Case of Infection-Provoked Macrophage Activation Syndrome in Mixed Connective Tissue Disease

Background Compared to systemic lupus erythematosus and adult-onset Still’s disease, mixed connective tissue disease (MCTD) is rarely associated with macrophage activation syndrome (MAS). Viruses, including cytomegalovirus (CMV), may potentiate MAS,[1] often in conjunction with an underlying connective tissue disease.[1-3] Despite this, reports of infection-provoked MAS in adults with MCTD remain very rare.[2,3] Here we describe a case of MAS in a patient with MCTD and concurrent CMV viremia and Clostridioides difficile colitis. Case Report A 65-year-old male was diagnosed with MCTD after presenting with pulmonary arterial hypertension, presumed glomerulonephritis, Raynaud’s phenomenon, and polyarthritis on a background of coronary artery disease and recent NSTEMI requiring stent placement. Investigation revealed a positive ANA (≥1:640, speckled pattern); high-positive anti-RNP-A, Sm/RNP, Ro60/SSA, Ro52/TRIM21, and SSB; and proteinuria. Right heart catheterization and renal biopsy were deferred given dual-antiplatelet therapy and spontaneous renal recovery. He received methylprednisolone prior to a prednisone taper and initiated mycophenolate mofetil (MMF), hydroxychloroquine, macicentan, and tadalafil. He subsequently presented with watery diarrhea, fever (38.5°C), malaise, weight loss and arthralgia. Infectious work-up revealed CMV viremia (serum viral load >4 million/mL) and C. difficile colitis, for which he initiated ganciclovir and oral vancomycin. He was found to have new bicytopenia (hemoglobin 78 g/L, platelet count 175 ×10^9/L), hyperferritinemia (peak 6751 μg/L), hypertriglyceridemia (3.47 mmol/L), hypofibrinogenemia (nadir 1.0 g/L), and elevated aspartate aminotransferase (101 units/L). His C-reactive protein was 21.0 mg/L (peak) and his complement C3 and C4 were normal. Both hematology and rheumatology were consulted, and the patient was diagnosed with MAS. Bone marrow biopsy was deferred given overwhelming evidence for MAS. His MMF was held for diarrhea, and he was initiated on methylprednisolone (250 mg daily for 3 consecutive days, followed by taper) and anakinra (100 mg subcutaneously daily, titrated to 3-times daily) with clinical and biochemical improvement. Conclusion We found only 2 other published English-language adult cases of MAS in conjunction with MCTD in the context of infection. One case was related to histoplasmosis,[2] and the other to an unspecified infection. [3] It is well known that infections can trigger MAS,[1] and while rare, in the appropriate clinical context, MAS should be considered in patients with MCTD who present with an infection and are not improving with standard treatment and whose biochemical parameters suggest MAS. References [1.] Atteritano M. Eur Rev Medi Pharmacol Sci 2012;16:1414-24. [2.] Kawashima H. Intern Med 2025;64:141-6. [3.] Dhote R. Arthritis Rheum 2003;49:633-9.

Open article ↗



2026-06-08 | Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra.

Hyperinflammatory responses substantially contribute to morbidity and mortality in severe COVID-19 and share features with secondary hemophagocytic lymphohistiocytosis and macrophage activation syndrome. The Hyperinflammation in COVID-19 (HIC) criteria allow early diagnosis and may provide a framework for dynamic treatment monitoring. We retrospectively analyzed 218 hospitalized patients with hyperinflammation (HIC ≥35) who received anakinra at a tertiary referral center. The daily anakinra dose (100-800 mg/day, administered intravenously or subcutaneously) was adjusted according to clinical and laboratory parameters. The primary outcome was in-hospital mortality. Secondary outcomes included time to ≥50% CRP reduction, ICU admission, mechanical ventilation, and dynamic changes in ΔHIC and inflammatory biomarkers. Overall mortality was 12.8%. Survivors achieved earlier CRP reduction than non-survivors (3.1 vs. 4.7 days) and showed a progressive decline in HIC, whereas non-survivors had persistently elevated or rising scores. Divergence in ΔHIC and other parameters, including neutrophil count, D-dimer, LDH, procalcitonin, and creatine kinase, emerged within 3-4 days. ROC analysis demonstrated that HIC on the day of anakinra initiation and at the final assessment discriminated survivors from non-survivors (AUC 0.75, p < 0.001; cut-offs 70.8 and 66.5, with high sensitivity but moderate specificity), whereas baseline and first-response-day HIC had limited predictive value (AUC approximately 0.50-0.55) . These findings support the HIC score as both a diagnostic and dynamic monitoring tool during IL-1 blockade. Initiating anakinra when HIC is ≥35 but <70, and reassessing treatment response after 3-4 days using ΔHIC together with CRP kinetics, may help optimize outcomes.

Open article ↗



2026-04-21 | Therapeutic challenges of concurrent pneumonia and disease flare in a patient with Still’s disease and recurrent macrophage activation syndrome

Introduction Still’s disease belongs to non-familial autoinflammatory systemic disorders. Prior distinction of this condition into two separate entities: the systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD), is obsolete, and European Alliance of Associations for Rheumatology recommends that it should be considered as one disease. Case description Patient at age 30, diagnosed with sJIA at 4. The first treatment was high doses of glucocorticosteroids (GCs). At that time, the patient 3 times develop macrophage activation syndrome (MAS). Since 2016, methotrexate (MTX) was prescribed, and in 2022, leflunomide was added as a second drug, but the patients took them irregularly. In 2022, due to a persistent subfebrile state and recurrent arthritis, he was qualified for treatment with tocilizumab at a dose of 400 mg applied in infusions every 4 weeks. Due to a remission state since 2023 multiple attempts to prolong the time between applications were made, but they failed. Finally, in 2025, the duration between dosages was successfully extended to 8 weeks. During therapy, the prior treatment with MTX was recommended but not taken by patients. In January 2026, the patient reported pain in multiple joints, fever, sore throat and rash on his trunk. In addition, patient complains of severe pain in his chest. In laboratory tests, the inflammatory indicators were very high. In the high-resolution computed tomography of the chest, the symptoms of pneumonia were described. Treatment with levofloxacin and a pulse of i.v. methylprednisolone has been introduced with subsequent treatment with prednisolone at a dose 1 mg/kg/day. The regression of changes in the lungs was achieved, the fever did not subside, and inflammatory indicators were still high, pointing to the development of MAS. After administration of tocilizumab, due anakinra was not available, complete remission was achieved. Although the interval from the end of pneumonia treatment was only one week. Due to the reluctance to use MTX, treatment with cyclosporine at a dose of 3 mg/kg/day was proposed. Conclusions The occurrence of severe pneumonia raises concerns about the safety of further tocilizumab treatment. A possible therapeutic option for this patient is interleukin-1 (IL-1) blockade, e.g. anakinra, which, according to the recommendations of the British Society for Rheumatology, is preferred in severe systemic disease over IL-6 blockade. In addition, it has been proven to be safe to use anakinra even in patients with sepsis, so it could be a therapeutic option in this case. Similar data for the use of tocilizumab in bacterial infection is lacking.

Open article ↗



small molecules
2026-09-11 | Unmasking Macrophage Activation Syndrome in Vexas Syndrome: A Diagnostic Challenge.

Vacuoles, E1 Enzyme, X-linked, Auto-inflammatory, Somatic (VEXAS) syndrome is a late-onset autoinflammatory disease caused by somatic mutations in the UBA1gene. Macrophage activation syndrome (MAS) is a rare but life-threatening hyperinflammatory condition whose association with VEXAS syndrome remains poorly described. We report three cases of MAS occurring in men aged 65 to 72 years with genetically confirmed VEXAS syndrome. In all cases, MAS was characterized by fever, recent-onset cytopenias, marked hyperferritinaemia, and a high probability of MAS according to the H-score (>93%). Bone marrow examination demonstrated haemophagocytosis in two patients and numerous activated macrophages in one. Extensive investigations failed to identify infectious, malignant, or drug-related triggers. In one patient, MAS preceded the diagnosis of VEXAS syndrome by several years. In the two others, MAS occurred during the course of established VEXAS disease and was considered a manifestation of disease flare. Treatment included high-dose corticosteroids, with additional anakinra in one patient and etoposide in another, resulting in rapid clinical and biological improvement. One patient experienced MAS relapse following granulocyte colony-stimulating factor exposure during azacitidine treatment, whereas no recurrence was observed in the other two patients during follow-up. MAS appears to be an underrecognized and potentially severe complication of VEXAS syndrome that may occur in the absence of an identifiable infectious or malignant trigger. Diagnostic overlap between both conditions may delay recognition. MAS should be suspected in VEXAS patients presenting with acute cytopenias, marked hyperferritinaemia, and organ involvement. Early use of the H-score, bone marrow examination, and prompt immunosuppressive treatment are essential to improve outcomes. Macrophage activation syndrome (MAS) may represent a severe flare manifestation of Vacuoles, E1 Enzyme, X-linked, Auto-inflammatory, Somatic (VEXAS) syndrome, even in the absence of an identifiable infectious, malignant, or drug-related trigger.The diagnosis of MAS can be challenging in VEXAS syndrome because both conditions share overlapping features, including systemic inflammation, cytopenias, hyperferritinaemia, and bone marrow abnormalities.Recent-onset cytopenias, marked hyperferritinaemia, and organ involvement in patients with VEXAS syndrome should prompt early assessment for MAS using the H-score and bone marrow examination, allowing rapid initiation of immunosuppressive therapy.

Open article ↗



2026-09-02 | Ruxolitinib for rheumatic disease-associated macrophage activation syndrome in children: a retrospective cohort study.

Macrophage activation syndrome (MAS) is a severe, life-threatening complication in pediatric rheumatic diseases. Current treatments are predominantly based on glucocorticoids; however, their long-term use is associated with significant adverse effects. Ruxolitinib, a Janus kinase (JAK) inhibitor, has emerged as a potential treatment option, but clinical evidence in pediatric populations remains limited. This study aimed to evaluate its efficacy and safety in pediatric patients with rheumatic disease-associated MAS (RD-MAS). We retrospectively reviewed the medical records of pediatric patients with RD-MAS treated at Shenzhen Children's Hospital between January 2021 and December 2025. Eligible patients had a confirmed rheumatic disease, fulfilled the 2016 EULAR/ACR classification criteria for MAS, and had complete clinical, laboratory, treatment, and follow-up data. Patients who received ruxolitinib in addition to conventional immunosuppressive therapy were compared with contemporaneous patients treated with conventional immunosuppressive therapy alone. The primary outcome was time to complete remission (CR). Secondary outcomes included remission rates during follow-up, changes in laboratory parameters, glucocorticoid-sparing effect, cumulative glucocorticoid exposure, and adverse events. A total of 21 patients with RD-MAS were included, of whom 10 received ruxolitinib (ruxolitinib group) and 11 received conventional therapy alone (non-ruxolitinib group). In the ruxolitinib group, 10 patients (6 males, 4 females) had underlying diagnoses of systemic juvenile idiopathic arthritis (sJIA, n = 7), systemic lupus erythematosus (SLE, n = 1), or other connective tissue diseases (n = 2). All patients presented with active disease at baseline. 30% (3/10) of patients achieved CR by week 4, and all patients achieved CR by week 48. By week 8, the median prednisone-equivalent dose decreased from 4 mg/kg/day to 0.4 mg/kg/day, and all patients successfully discontinued glucocorticoids by week 48 while maintaining remission. No significant difference in time to CR or infection rates was observed between groups. However, the ruxolitinib group demonstrated significantly lower cumulative glucocorticoid exposure during follow-up. Ruxolitinib-based therapy was associated with sustained disease control and a significant glucocorticoid-sparing effect in pediatric RD-MAS. These findings support that ruxolitinib may serve as a promising steroid-sparing strategy with favorable efficacy and safety for pediatric RD-MAS, although larger prospective studies are warranted.

Open article ↗



2026-08-23 | Myeloid IRF5 is required for TLR7-driven inflammatory hemophagocyte differentiation and Macrophage Activation Syndrome

ABSTRACT In TLR7-driven macrophage activation syndrome (MAS), inflammatory hemophagocytes (iHPCs) differentiate from Ly6C HI monocytes, phagocytose red blood cells and promote disease, including anemia and thrombocytopenia. We demonstrate here that IRF5 is required for iHPC differentiation and MAS in TLR7-overexpressing (TLR7.1) mice. Both constitutive and myeloid-specific Irf5 deletion reduced iHPCs and improved anemia, thrombocytopenia and survival. Furthermore, therapeutic inhibition of IRF5 ameliorated MAS features and reduced splenic and circulating iHPCs. While cell-intrinsic IRF5 expression was required for iHPC differentiation, it was not required for TLR7.1 Ly6C HI monocyte differentiation and monocyte transcriptional programs. We further show that the transcriptome and chromatin landscape changed dramatically as iHPCs differentiated from TLR7.1 Ly6C HI monocytes. Many transcriptional programs gained in iHPCs were enriched in genes associated with IRF5-binding accessible chromatin regions, including those associated with NF-κB signaling, cytokine and chemokine production, and complement activation. Our data suggest that IRF5 collaborates with other transcription factor families, including NF-κB, ETS and AP1 members, to regulate iHPC gene programs. Together, our findings demonstrate that expression of IRF5 in myeloid cells is critical for MAS, for iHPC differentiation, and acts broadly across iHPC-specific gene programs in TLR7-driven inflammation. SUMMARY In TLR7-driven MAS, specialized monocyte-derived inflammatory hemophagocytes promote disease, including anemia and thrombocytopenia. Thulin, Lu et al. show that myeloid cell IRF5 is required for iHPC differentiation from Ly6C HI monocytes and for MAS, and that IRF5 likely partners with other transcription factors, including NF-κB, to shape iHPCs programs.

Open article ↗



2026-08-12 | Ruxolitinib combined with corticosteroids for the successful treatment of kawasaki disease-associated macrophage activation syndrome: a case report.

To explore the diagnostic challenges of Kawasaki disease (KD)-associated macrophage activation syndrome (MAS) and the therapeutic value of ruxolitinib combined with corticosteroids. We retrospectively analyzed the clinical data of one pediatric patient with KD-associated MAS and conducted sorting and analysis of relevant published literature. A 14-month-old male infant presented with fever and rash and was diagnosed with severe KD. Despite initial treatment with intravenous immunoglobulin (IVIG) and aspirin, he developed persistent fever, progressive cytopenia, hepatosplenomegaly, hypofibrinogenemia, hyperferritinemia, reduced NK-cell activity, and extremely elevated soluble interleukin-2 receptor (sCD25), fulfilling the HLH-2004 criteria for MAS. He was successfully treated with ruxolitinib plus methylprednisolone, with rapid resolution of fever, recovery of blood counts, and improvement in coagulation and inflammatory markers. KD-associated MAS is rare but life-threatening. Early recognition of warning signs and prompt initiation of ruxolitinib-based combination therapy can effectively control cytokine storm and improve clinical outcomes.

Open article ↗



2026-08-06 | Unraveling Immune Dysregulation in ZNFX1 Deficiency: From Interferonopathies to Macrophage Activation Syndrome

Abstract Purpose ZNFX1 interferes with early viral replication after exposure to type I interferon, and interacts with mitochondrial antiviral sensors (MAVS) leading to a balanced expression of interferon-stimulated genes (ISGs). ZNFX1 deficiency mimics systemic autoinflammatory diseases and accurate identification may prevent early mortality. We compare a homozygous ZNFX1 frameshift mutation patient to subjects with known interferonopathies. We explore the association between this mutation, unregulated ISGs, and macrophage activation syndrome (MAS). Methods Study participants included our index patient, other patients with well-characterized interferonopathies, and healthy participants. We performed western blotting for ZNFX1 and whole Blood mRNA-seq, RT-qPCR, ELISA, and Olink Proteomics analysis to assess cytokine production and the underlying immune dysregulation. Results Our patient had elevated expression of interferon-inducible genes compared to healthy controls, but levels were comparable to subjects with known interferonopathies. Gene sequencing revealed a novel homozygous ZNFX1 frameshift variant resulting in a truncated protein. Transcriptomic analysis pointed to the top 3 cytokine upstream regulators, tumor necrosis factor (TNF), IL-1β, and interferon-gamma. ZNFX1 deficient patients appear to have a clinical profile that differs from classical type I interferonopathies, including features such as thrombotic microangiopathy (TMA) and a higher frequency of MAS. Conclusions ZNFX1 deficiency is an immune dysregulation disorder characterized by a robust type I interferon signature combined with elevated inflammatory cytokines, leading to severe early-onset multisystem inflammatory disease. Characterizing the immune profile allows targeted short-term treatments that may prolong life.

Open article ↗



cell therapies
2025-09-01 | Allogeneic haematopoietic stem cell transplantation for severe Still's disease: a retrospective report of three paediatric patients.

Severe forms of systemic JIA (sJIA), also called paediatric-onset Still's disease are associated with two major life-threatening complications: macrophage activation syndrome (MAS) and severe lung disease. Patients are usually resistant to conventional synthetic (cs) DMARDs, biologic (b) DMARDs, and targeted synthetic (ts) DMARDs. Recently, allogeneic haematopoietic stem cell transplantation (HSCT) has been performed in a small number of patients with refractory and life-threatening disease. We aimed to report outcomes and complications of allogeneic HSCT in patients with severe, refractory sJIA treated at our centre. We conducted a retrospective, observational, single-centre study in a tertiary paediatric immunology care centre (Necker Hospital, Paris, France). We report three sJIA patients who underwent allogeneic HSCT at a median age of 3.5 years. All had recurrent MAS; two had lung disease and the HLA-DRB1*15 haplotype, associated with severe delayed hypersensitivity to IL-1/IL-6 inhibitors. Donors were matched sibling donors for the first and third patient, and matched unrelated donor for the second patient. They presented multiple post-graft complications: graft-vs-host disease, infections, thrombotic microangiopathy and severe inflammatory complications on previously affected organs, such as skin and lungs. At a median follow-up of 22 months (20-33) after transplantation, they were all in remission with full-donor chimerism and were off immunosuppressive treatment. Allogeneic HSCT can be an effective salvage therapy in patients with refractory sJIA. However, the risk of post-transplant endothelial complications and severe inflammation in previously affected organs, such as joints, skin and lungs deserves particular attention.

Open article ↗



2025-06-01 | POS1430 GENETIC LANDSCAPE OF ADULT-ONSET STILL'S DISEASE WITH MACROPHAGE ACTIVATION SYNDROME: IDENTIFYING KEY RISK LOCI FOR DISEASE MECHANISMS AND PERSONALIZED TREATMENT


Abstract

Background:

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are severe, life-threatening systemic hyperinflammatory syndromes. They can arise from genetic defects as well as various triggers, including infections, malignancies, and autoimmune diseases. MAS is most recognised and best studied in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Currently, research on the underlying pathogenesis of MAS and its treatment options remains insufficient. Recently, the field of genomics has garnered increasing attention.

Objectives:

The objective of this study is to identify the genetic variants associated with AOSD-MAS susceptibility and to elucidate their connections to specific target genes. Such insights are critical for advancing the clinical translation of genetic discoveries, thereby enhancing the accuracy of diagnostic genetic screenings and informing personalized therapeutic strategies.

Methods:

In this study, we performed whole-exome sequencing (WES) on a cohort of AOSD patients to identify potential genetic variations, followed by Sanger sequencing for validation. RNA sequencing (RNA-seq) was conducted to explore gene expression profiles. Statistical analyses were carried out using Fisher's exact test (two-sided) to assess associations, and survival analysis was employed to evaluate outcomes.

Results:

This study investigated the genetic predisposition of AOSD-MAS, highlighting the critical involvement of known causative genes for primary HLH (pHLH-KG) and the candidate genes in AOSD-MAS. Among the 72 AOSD-MAS patients, 19 individuals (19/72, 26.39%) harbored mutations in pHLH-KG genes, including LYST, PRF1, STX11, UNC13D, NLRC4, STXBP2, AP3B1, CTPS1, RASGRP1, NCKAP1L, and RC3H1. Gene level comparisons demonstrated that ADGRE2, TGFB1, C6, IKZF3, MPO, POLD1, LIFR, IL15RA, and FANCC were significantly enriched in AOSD-MAS compared to AOSD without MAS (AOSD-nMAS), with notable differences (log2OR > 1 or infinite, p-value < 0.05). At the variant level, significant differences were observed for LYST p.I2666N, STX11 p.A125V, POLA1 p.V539M, LRBA p.E88A, ERCC4 p.G912R, and ADGRE2 p.C29Y (p-value < 0.05). These findings strongly suggest that ADGRE2 plays a pivotal role in the pathogenesis of AOSD-MAS. Additionally, we also conducted gene-phenotype correlation analysis, which revealed that CSF2RB and MECOM were significantly more prominent in refractory AOSD-MAS. In conclusion, the potential synergistic interactions among these genes may contribute critically to the development of AOSD-MAS.

Conclusion:

Our study identified mutations in known HLH-associated genes as well as new candidate genes in AOSD-MAS through WES. Gene-phenotype correlation analysis revealed differences in gene profiles across different clinical phenotypes, providing insights for the precision therapies for AOSD-MAS.

REFERENCES:

NIL.

Acknowledgements:

NIL.

Disclosure of Interests:

None declared. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.


Open article ↗



2025-03-07 | Influence of CAR T-cell therapy associated complications.

Since the introduction of chimeric antigen receptor (CAR) T-cell therapy, it has elicited an immense response in both targeted and residual cancers. Its clinical efficacy is often accompanied by a group of side effects that may become serious because of factors such as tumor burden, the extent of lymphodepletion, and the type of co-stimulus. It is also crucial to know the common toxicities associated with CAR T-cell therapy, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cardiotoxicity, metabolic disorders, pulmonary toxicity, macrophage activation syndrome (MAS), prolonged cytopenia, coagulation disorders, and potential off-target effects on various organs. If not well managed, these can be fatal. However, knowledge about molecular pathways, calcineurin inhibitors, IL-6 receptor antagonists, steroids, suppression of nitric oxide synthase, various therapeutic approaches, and other recent advances have been developed to mitigate the fatal results of various short-term and chronic adverse events related to CAR T-cell therapy. This study provides a comprehensive perspective on contemporary management strategies and presumed causative processes of CAR T-cell-related adverse effects, albeit with several limitations. When CAR T-cell complications, costs, and challenges of toxicity management are properly considered, the CAR T-cell therapy of the future will include a number of toxicity-escaping options.

Open article ↗



2024-08-08 | Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis.

Hemophagocytic lymphohistiocytosis (HLH) can be considered as a severe cytokine storm syndrome disorder. HLH typically manifests as a life-threatening inflammatory syndrome characterized by fevers, cytopenias, hepatosplenomegaly, and various other accompanying manifestations such as coagulopathy, hepatitis or liver failure, seizures or altered mental status, and even multi-organ failure. Standard up-front treatments do not always bring HLH into remission or maintain adequate response, and salvage or alternative therapies are often needed. For patients with genetic diseases that cause HLH, curative allogeneic hematopoietic cell transplantation is usually offered to prevent future episodes of life-threatening HLH. Here, we will discuss the options and approaches for salvage therapy and hematopoietic cell transplantation for patients with HLH.

Open article ↗



2024-06-22 | Optimization Strategies in CAR T-cell Therapy: A Comprehensive Evaluation of Cytopenia, HLH/MAS, and Other Adverse Events.

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for various hematological malignancies. Still, its remarkable efficacy is accompanied by unique adverse events that must be carefully managed. This comprehensive literature review evaluates the safety profile of CAR T-cell therapy, focusing on cytopenia, hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS), and other potential complications. Cytopenia, characterized by reduced blood cell counts, affects a significant proportion of patients, with rates of anemia, neutropenia, and thrombocytopenia reaching up to 60%, 70%, and 80%, respectively. Risk factors include high tumor burden, prior chemotherapy, and bone marrow involvement. Cytokine release syndrome (CRS) occurs in 13% to 77% of patients and is linked to the cytokine storm induced by CAR T cells, target antigen expression, and preexisting immune dysregulation. Other notable adverse events discussed are cytokine release syndrome, neurotoxicity, and infections. Understanding the mechanisms, risk factors, and management strategies for these adverse events is crucial for optimizing patient outcomes and unlocking the full potential of this revolutionary therapy. The review highlights the need for continued research, interdisciplinary collaboration, and evidence-based approaches to enhance the safety and efficacy of CAR T-cell therapy.

Open article ↗



antibodies
2026-09-11 | Macrophage activation syndrome in systemic lupus erythematous and Still's disease: distinct phenotypes shaped by the underlying diseases.

Macrophage activation syndrome (MAS) is a severe complication of Still's disease (SD-MAS), but may also, albeit rarely, complicate SLE (SLE-MAS). The clinical profile of SLE-MAS compared with SD-MAS remains unclear, as do the optimal treatment strategies. A retrospective multicentre cohort of adults with a history of SLE-MAS or SD-MAS was gathered from eight tertiary referral centres. MAS clinical/laboratory features, treatments and outcomes were compared; 'inaugural MAS' was defined if occurring within 6 months from the onset of the underlying disease. Exploratory multivariable profiling assessed for disease-specific features. The SLE-MAS group was also compared with large historical SLE cohorts to identify candidate risk signals. While SD-MAS aligned with the prototypical hyperinflammatory pattern (more marked hyperferritinemia, very high CRP, organomegaly and liver injury; 100% meeting 2016 ACR/EULAR/PRINTO criteria), SLE-MAS (92% meeting criteria) more often featured CNS dysfunction, less liver injury, greater degree of cytopenias including anaemia, with a strong signal of autoimmune haemolysis (73% direct Coombs [DCT] positivity). Therapeutically, IL-1 antagonism was used in seven SLE-MAS with mixed results without any rapid MAS resolution. Mucocutaneous disease, autoimmune haemolysis, CNS involvement, less pronounced female preponderance and much higher DCT positivity dominated the SLE-MAS phenotype compared with historical SLE cohorts comprising 1000, 2228 and 2055 cases each. SLE-MAS diverged from SD-MAS with less organomegaly and liver injury but more pronounced CNS involvement and hematological involvement, the latter strongly linked to red blood cell directed autoantibodies. These findings indicate that SLE-MAS pathogenesis may be divergent and require distinct therapeutic approaches beyond extrapolation from SD-MAS.

Open article ↗



2026-09-10 | Spatial transcriptomics reveals distinct phenotype of proliferating and interferon-activated T lymphocytes in macrophage activation syndrome driven liver inflammation in systemic juvenile idiopathic arthritis

Identify pathways and candidate biomarkers that distinguish various liver pathologies in systemic juvenile idiopathic arthritis (SJIA) with the focus on liver-predominant macrophage activation syndrome (SJIA-MAS). Formalin-fixed, paraffin-embedded liver tissues from SJIA-MAS ( n = 6), SJIA without MAS ( n = 1), autoimmune hepatitis (AIH, n = 7), familial HLH (FHLH, n = 6), steatohepatitis (SH, n = 3), and controls (Ctrl, n = 3) were analyzed by histology and using the NanoString GeoMx Digital Spatial Profiler (DSP). CD3E, CD68 and cytokeratin 8/18 antibodies were used to select regions enriched for T lymphocytes, macrophages, or hepatocytes, respectively. Spatially resolved gene expression data was Q3-normalized and subjected to principal component and clustering analysis. Differentially expressed genes were identified using Mann-Whitney U-test. Histologically, SJIA-MAS liver biopsies were distinguished by extensive portal and intra-sinusoidal expansion of activated CD163 + histiocytes and T lymphocytes (predominantly CD8+). Spatial transcriptomics revealed a markedly distinct phenotype in T lymphocyte enriched regions in SJIA-MAS liver tissue. In addition to pathways driving activation and survival, T lymphocyte regions in SJIA-MAS were distinguished by activation of IFNƔ-induced signaling including CXCL9 overexpression. Strong IFN-induced signatures were also observed in hepatocyte-enriched areas in SJIA-MAS and FHLH. T cell regions in SJIA-MAS could be distinguished by upregulated IFN-induced signaling. Considering that T cells have emerged as the main source of IFN-Ɣ in MAS, this may reflect an amplification loop contributing to uncontrolled activation and expansion of these cells. Our data also suggest that in SJIA-MAS, IFN-Ɣ may be a direct driver of liver injury and, therefore, serve as a therapeutic target.

Open article ↗



2026-09-07 | AMETHYST: a Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-refractory Macrophage Activation Syndrome Complicating Still's Disease.

Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life-threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult-onset Still's disease [AOSD]). AMETHYST aimed to describe real-world treatment patterns and outcomes in glucocorticoid (GC)-refractory MAS complicating Still's disease. In this retrospective cohort study, medical data from January 1, 2012, to March 31, 2023, were abstracted from charts of all eligible patients across eight sites in Europe, Canada, and the US for index MAS episodes (occurring between January 1, 2012, and September 30, 2022, and meeting eligibility criteria). Overall, 55/64 (86%) included patients had sJIA and 9/64 (14%) had AOSD. Most patients (53/64 [82.8%]) were children at index (median age: 7.0 years). MAS was characterized by rash (60.4%), fever (52.8%), and hepatic involvement (49.1%). All patients received GCs; most were also treated with anakinra (48/64 [75%]) and/or ciclosporin (33/64 [51.6%]). Normalization of 7 (complete MAS laboratory remission) or ≥3 (partial remission) prespecified laboratory parameters occurred in 7/64 (10.9%) and 41/64 (64.1%) patients, respectively. GCs were tapered in 50/64 (78.1%) patients (median: 39.9 days). Per investigator assessment of clinical signs/symptoms for the index MAS episode, 24/64 (37.5%) and 26/64 (40.6%) patients had a complete and partial response, respectively. MAS recurred in 20/64 (31.3%) patients. There were 7/64 (10.9%) deaths; estimated 1-year survival probability was 93.75%. Low MAS laboratory remission rates and toxicities of high-dose GCs combined with other treatments highlight the need for safer, more effective therapies.

Open article ↗



2026-09-05 | Macrophage activation syndrome as a rare complication of atypical Kawasaki Disease

No abstract abstract

Open article ↗



2026-09-02 | Analysis code for: VEXAS and Macrophage Activation Syndrome — clinical and multiomic approach of a unique hyperinflammatory clinical dyad

Analysis code and de-identified source data reproducing the cytokine, flow-cytometry, Olink Reveal proteomic and whole-exome summary results reported in the manuscript. Raw sequence data and the full proteomic plate export are not included; they are deposited under controlled access (see the manuscript's Data Availability statement).

Open article ↗



other
2026-09-26 | The Silent Vehicle: Validating the Biological Signals and Noises of Baculovirus Vectors in Macrophage-Targeted Vaccines.

The Baculovirus Expression Vector System (BEVS) is an established eukaryotic platform for high-yield recombinant protein production and is widely utilized for generating vaccine antigens, including recombinant classical swine fever virus E2 glycoprotein, African swine fever virus structural proteins (p72, p30, and p54), and porcine reproductive and respiratory syndrome virus envelope proteins GP5 and M. These antigens interact with macrophage-associated receptors, including CD163 and CD206, to modulate immune responses through macrophage polarization. However, whether baculovirus vector-derived components intrinsically influence macrophage polarization remains unclear, raising concerns regarding potential impacts on biological activity, vaccine efficacy, and downstream purification strategies. In this study, an M2-like tumor-associated macrophage (TAM) model capable of repolarizing toward an M1-like phenotype was established to distinguish the transcriptomic effects of the baculovirus vector control (VC) from those of the recombinant antigen (A1). Comparative RNA sequencing, Gene Set Enrichment Analysis (GSEA), functional enrichment analyses, and linear regression analysis were performed to evaluate vector- and antigen-associated transcriptional responses. Comprehensive transcriptomic analysis showed that VC treatment induced only minimal transcriptomic alterations, with limited immune-related pathway enrichment and expression profiles that remained highly similar to those of untreated M2-like TAMs. Furthermore, linear regression analysis demonstrated negligible correlations between VC-induced and A1-induced transcriptional responses indicating that the limited changes associated with the vector backbone did not correspond to the receptor-mediated immune responses elicited by the recombinant antigen. In contrast, A1 stimulation induced distinct transcriptional reprogramming characterized by enrichment of pro-inflammatory and immune-activation pathways and a shift toward an M1-like macrophage phenotype. These findings suggest the negligible correspondence between VC- and A1-induced transcriptional profiles further supports the transcriptomic noises and signals of the baculovirus vector and inserted proteins, reinforcing its suitability as a platform for macrophage-targeted vaccine development while providing a basis for future optimization of downstream purification strategies.

Open article ↗



2026-03-08 | Is a variant of uncertain significance always 'insignificant'? A systematic review on PRF1 A91V in Hemophagocytic Lymphohistocytosis and comparative analysis with Still's disease.

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory disorder that may arise secondary to rheumatic diseases such as Still’s disease, where macrophage activation syndrome (MAS) represents its clinical counterpart. The pathogenic significance of the PRF1 A91V variant remains uncertain, although functional data suggest partial perforin dysfunction and a possible contribution to late-onset or atypical HLH. This study aimed to clarify the clinical implications of the PRF1 A91V variant through a systematic review of published HLH and MAS cases and a comparative analysis with a single-center Still’s disease cohort. A total of 20 studies, including 38 individual HLH or MAS cases carrying the PRF1 A91V variant, were identified. The median age at diagnosis was 22 years, and 18.4% of patients were homozygous. Fever (82.6%), splenomegaly (57.9%), and hepatomegaly (36.8%) were the most frequent clinical findings. Anemia (57.1%) and thrombocytopenia (85.7%) were the predominant laboratory abnormalities, accompanied by marked hyperferritinemia (median 9319 ng/mL). Compared with 43 active Still’s disease cases, PRF1-mutated HLH patients showed significantly higher rates of cytopenias, hepatomegaly, and central nervous system involvement, together with substantially elevated ferritin levels (9,193 vs 800 ng/mL, p = 0.0023), whereas C-reactive protein levels were comparable. Receiver-operating characteristic analysis identified a ferritin cutoff of 7000 ng/mL (sensitivity 63.2%, specificity 84.6%) as the optimal discriminator for PRF1 A91V positivity. In multivariate regression, ferritin ≥ 7,000 ng/mL remained the only independent predictor (OR 17.3, 95% CI 2.0–146.3, p = 0.009). Patients carrying the PRF1 A91V variant represent a distinct subgroup within the spectrum of hyperinflammatory syndromes. Extreme hyperferritinemia combined with cytopenias should raise suspicion for perforin-related HLH rather than cytokine-driven MAS or classic Still’s disease. Recognition of this variant as a risk-modifying allele may guide early genetic testing and therapeutic decisions, including consideration of advanced interventions in selected cases. The online version contains supplementary material available at 10.1186/s13023-026-04296-4.

Open article ↗



2025-06-27 | Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study.

Background: The introduction of biological drugs into clinical practice for the treatment of children with systemic juvenile idiopathic arthritis (sJIA) allows disease control but increases the risk of infectious events. Infectious events cause immunosuppressive therapy interruptions, leading to disease flare and life-threatening complications, namely macrophage activation syndrome. Our study aimed to evaluate the efficacy and safety of simultaneous vaccination against pneumococcal and Haemophilus influenzae type b (Hib) in children with sJIA. Methods: This study included 100 sJIA patients receiving immunosuppressive therapy who were simultaneously vaccinated against pneumococcal and Haemophilus influenzae type b (Hib) infections. The mean age of disease onset was 5.5 years. The median age at vaccination was 10 ± 4.5 years. Clinical and laboratory parameters of sJIA activity, immunization efficacy, and safety, including anti-SP and anti-Hib IgG antibodies, as well as all vaccination-related adverse events (AEs), were recorded in every patient before, 3 weeks after, and 6 months after vaccination. Results: At the time of vaccination, 29% of patients did not meet the criteria for the inactive disease stage, as defined by C. Wallace: active joints were present in 34.5% of patients, systemic manifestations (rash and/or fever) were present in 41.3%, and 24.2% of patients had solely inflammatory laboratory activity. The protective titer of anti-SP and anti-Hib IgG antibodies was detected in the majority of patients 3 weeks after vaccination (100% and 93%, respectively). The results remained unchanged (99% and 92%, respectively) for 6 months of follow-up, compared to the baseline (91% and 37%, p = 0.000001). Anti-SP IgG and anti-Hib titers raised from 48.3 (18.2; 76.5) and 0.64 (0.3; 3.2) U/mL at the baseline to 103.5 (47.3; 185.4) and 4 (3.5; 4.2) U/mL at D22 and 105 (48.7; 171.8) and 4 (3.8; 4) U/mL (EOS), respectively. Immunosuppressive therapy regimens (combined therapy or biological disease-modifying antirheumatic drug monotherapy) did not influence the immunogenic efficacy of vaccination. The incidence of infectious complications (p = 0.0000001) and antibiotic prescriptions (p = 0.0000001) decreased by more than two times, to 29.9 and 13.8 events per 100 patient months, respectively, within 6 months after vaccination-the average duration of acute infectious events was reduced by five times after immunization (p = 0.0000001). Vaccination did not lead to disease flare: the number of patients with active joints decreased by half compared to the baseline, and the number of patients with systemic manifestations decreased by six times. All vaccine-associated adverse events were considered mild and resolved within 1-2 days. Conclusions: Simultaneous vaccination against pneumococcal and Hib infections in sJIA children is an effective and safe tool that reduces the number and duration of infectious events and does not cause disease flare-ups.

Open article ↗



2025-04-16 | Macrophage Activation Syndrome in Adult-Onset Still's Disease: Challenges in Early Detection and Management.

Adult-onset Still's disease (AOSD) is an immunological disorder that manifests with fever, evanescent rash, leukocytosis, and arthralgia. One of the most severe complications of AOSD is macrophage activation syndrome, a life-threatening complication characterized by hyperactivation of the immune system and multiorgan dysfunction. This case report describes a 24-year-old female who developed macrophage activation syndrome in the setting of AOSD. Initially, she developed heterogeneous and nonspecific symptoms of fever, pharyngitis, rash, lymphadenopathy, and migratory arthralgia after a trip to Mexico. Thus, the diagnosis and appropriate treatment were delayed. Although her symptoms were temporarily relieved with oral steroids, she worsened clinically. She developed a widespread rash, persistent fever, a very high ferritin level (29,972 ng/mL), and elevated liver enzymes with mild hepatosplenomegaly, raising concern for macrophage activation syndrome. After ruling out infections, she was diagnosed with AOSD, and treatment with intravenous steroids was started, resulting in clinical improvement. Macrophage activation syndrome is a rare but fatal complication. Early recognition, particularly with elevated ferritin, liver dysfunction, and thrombocytopenia, is very important. Early intervention with glucocorticoids and biologics like anakinra is crucial for improving outcomes. The patient is in remission with ongoing follow-up with rheumatology.

Open article ↗



2024-10-29 | Functional role of UNC13D in immune diseases and its therapeutic applications.

UNC13 family (also known as Munc13) proteins are evolutionarily conserved proteins involved in the rapid and regulated secretion of vesicles, including synaptic vesicles and cytotoxic granules. Fast and regulated secretion at the neuronal and immunological synapses requires multiple steps, from the biogenesis of vesicles to membrane fusion, and a complex array of proteins for each step. Defects at these steps can lead to various genetic disorders. Recent studies have shown multiple roles of UNC13D in the secretion of cytotoxic granules by immune cells. Here, the molecular structure and detailed roles of UNC13D in the biogenesis, tethering, and priming of cytotoxic vesicles and in endoplasmic reticulum are summarized. Moreover, its association with immune diseases, including familial hemophagocytic lymphohistiocytosis type 3, macrophage activation syndrome, juvenile idiopathic arthritis, and autoimmune lymphoproliferative syndrome, is reviewed. Finally, the therapeutic application of CRISPR/Cas9-based gene therapy for genetic diseases is introduced.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

1 orphan drug designation for Macrophage activation syndrome.

1 orphan drug designation for Macrophage activation syndrome.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

dusquetide

peptides

FDA
2016-08-10

—

Soligenix, Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.